Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 4 Interventional

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

ClinicalTrials.gov ID: NCT06572228

Public ClinicalTrials.gov record NCT06572228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication. The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medication. The type of asthma medication that will be used is a combination inhaled corticosteroid and long-acting beta-agonist (referred to as an ICS/LABA). Some patients may also receive an additional asthma medication called a long-acting muscarinic antagonist (referred to as a LAMA) if they are already receiving a LAMA. The study is also looking at: • What side effects may happen from taking dupilumab

Study identification

NCT ID
NCT06572228
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 4
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
120 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 25, 2024
Primary completion
Apr 23, 2027
Completion
Apr 23, 2027
Last update posted
May 21, 2026

2024 – 2027

United States locations

U.S. sites
51
U.S. states
22
U.S. cities
50
Facility City State ZIP Site status
Kern Research, Inc Bakersfield California 93301
Modena Allergy & Asthma, Inc. La Jolla California 92037
Antelope Valley Clinical Trials Lancaster California 93534
Ark Clinical Research, LLC Long Beach California 90815
Newport Native Md, Inc. Newport Beach California 92663
Childrens Hospital of Orange County Main Campus Orange California 92868
Raffi Tachdjian MD, Inc. Santa Monica California 90404
Bensch Clinical Research Stockton California 95207
Integrated Research of Inland, Inc. Upland California 91786
Allianz Research Institute Westminster California 92683
National Jewish Health Denver Colorado 80206
St Francis Medical Institute Clearwater Florida 33765
Florida Lung, Asthma and Sleep Specialists (FLASS) - Celebration Kissimmee Florida 34746
Clinical Site Partners, LLC DBA Flourish Research Winter Park Florida 32789
Treasure Valley Medical Research Boise Idaho 83706
Sneeze Wheeze and Itch Associates Normal Illinois 61761
Asthma and Allergy Center of Chicago River Forest Illinois 60305
Endeavor Health, Skokie Campus Skokie Illinois 60077
University of Kansas Medical Center Kansas City Kansas 66160
Bluegrass Allergy Research Lexington Kentucky 40509
Family Allergy and Asthma Research Institute Louisville Kentucky 40217
Allergy & Asthma Specialists, P.S.C. Owensboro Kentucky 42301
Paul A. Shapero, M.D. Bangor Maine 04401
Massachusetts General Hospital Boston Massachusetts 02114
Michigan Medicine Ann Arbor Michigan 48109
Henry Ford Hospital Detroit Michigan 48202
Clinical Research Institute, Inc. Minneapolis Minnesota 55402
Washington University School of Medicine St Louis Missouri 63119
Montana Medical Research Missoula Montana 59808
The Asthma and Allergy Center Bellevue Nebraska 68123
Henderson Clinical Trials Henderson Nevada 89052
Certified Research Associates Cortland New York 13045
New York Medical College Hawthorne New York 10532
Northwell Health at ENT & Allergy Associates New York New York 10016
Rochester Regional Health - Alexander Park - Allergy, Immunology & Rheumatology Rochester New York 14607
Cincinnati Childrens Hospital and Medical Center Cincinnati Ohio 45229
Allergy Asthma and Clinical Research Center Oklahoma City Oklahoma 73120
Clinical Research Associates of Central PA DuBois Pennsylvania 15801
University of Pittsburgh Asthma and Environmental Health Lung Institute Pittsburgh Pennsylvania 15213
Pulmonology Associates Inc. Wynnewood Pennsylvania 19096
Dharma MD PA d/b/a Southwest Family Medicine Associates Dallas Texas 75235
Premier Pulmonary Critical Care and Sleep Medicine Denison Texas 75020
Western Sky Medical Research El Paso Texas 79912
Baylor College of Medicine - Section of Pulmonary and Critical Care Houston Texas 77030
Texas Children's Hospital Houston Texas 77030
Metroplex Pulmonary and Sleep Center, PA McKinney Texas 75069
Lung Sleep Research Institute North Richland Hills Texas 76180
South Texas Allergy & Asthma Medical Professionals (STAAMP) Research San Antonio Texas 78229
Allergy & Asthma Care of Waco Waco Texas 76712
Intermountain Medical Center - Murray (Pulmonary Medicine) Murray Utah 84107
Inova Fairfax Hospital Falls Church Virginia 22042

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06572228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 21, 2026 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06572228 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →